Obsessive-compulsive disorder responds to first-line treatment — a combination of high-dose SSRIs and exposure and response prevention (ERP) therapy — in only about half of patients, leaving a substantial population with intrusive thoughts, compulsive behaviors, and a quality of life degraded by the relentlessness of a brain that cannot seem to stop amplifying its own alarm signals. For these patients, the standard clinical conversation often dead-ends at augmentation strategies with limited evidence and significant side effect burdens. Cassidy Boyer, CRNA, works with OCD patients at Mend the Mind in Livingston who have exhausted conventional options, and she applies the same honest, evidence-grounded evaluation to OCD treatment as she brings to every condition she treats.
The Neurobiology of OCD and Ketamine’s Mechanism
The neurobiology of OCD has been increasingly well characterized over the past three decades, centered primarily on hyperactivity in the cortico-striato-thalamo-cortical (CSTC) loops — the neural circuits connecting the prefrontal cortex, striatum, and thalamus that are responsible for initiating and terminating repetitive behavioral sequences. In OCD, these circuits appear to get “stuck,” generating obsessional thoughts and driving compulsive behaviors that the patient cannot stop through willpower alone. First-line treatments — SSRIs and ERP — work by gradually reducing the hyperactivity of these circuits, but their effects are partial and slow for many patients.
Ketamine’s potential relevance to OCD comes from its mechanism at NMDA glutamate receptors. The CSTC loops implicated in OCD are glutamatergic circuits, and NMDA receptor dysfunction within these circuits has been hypothesized to contribute to their dysregulation. By transiently blocking NMDA receptor activity, ketamine may reduce the excitatory overdrive in these circuits in ways that serotonin modulation cannot achieve. Early clinical research, including a double-blind crossover trial published in the journal Biological Psychiatry, demonstrated rapid reductions in obsessive-compulsive symptoms following a single ketamine infusion in patients with OCD — effects that were not replicated by placebo saline. The evidence base is early but mechanistically coherent, and Cassidy follows it carefully. To understand more about how neuroplasticity and ketamine interact at a cellular level, our dedicated resource explores the science in depth.
Cassidy’s Evaluation Process for OCD Patients
At Mend the Mind, Cassidy does not present ketamine as an established OCD treatment with a well-defined protocol. She presents it as a clinically rational intervention for patients with treatment-resistant OCD who have completed adequate trials of first-line treatments and whose symptom burden remains severe. Her evaluation for OCD patients is rigorous: she reviews the specific OCD symptom domains, prior medication trials with dose and duration data, ERP therapy history and adequacy, and co-occurring diagnoses that may be contributing to the presentation — because depression, PTSD, and anxiety disorders frequently co-occur with OCD and may independently warrant ketamine treatment. Understanding the full diagnostic picture shapes what Cassidy recommends and why.
One aspect of ketamine’s application in OCD that Cassidy finds particularly interesting is the relationship between the rapid anti-obsessional effect and the window for therapeutic work. ERP therapy — the gold standard psychotherapy for OCD — is itself a process of neurological recalibration: exposing patients to feared stimuli without performing compulsions, and waiting until the anxiety subsides, literally retrains the CSTC circuits to respond differently over time. If ketamine reduces the intensity of obsessional activation, even briefly, it may create a window during which ERP-like exposure work can be engaged with less overwhelming distress — similar to the way ketamine may facilitate trauma processing in PTSD therapy. Cassidy incorporates this thinking into how she structures her OCD patients’ overall treatment architecture when they have active therapeutic relationships to bring that coordination to. Her approach to ketamine assisted psychotherapy reflects this integrative philosophy across conditions.
Honest Protocol Design in the Absence of Standardization
One barrier to ketamine treatment for OCD in Montana is the absence of well-defined clinical protocols. Unlike IV ketamine therapy for depression, where the four-to-six infusion series has become a de facto standard informed by research, OCD ketamine protocols are less standardized and require clinical judgment to design. Cassidy is transparent about this with every OCD patient: she explains what the published research shows, how she approaches protocol design based on the available evidence, and what the realistic range of outcomes includes. She does not promise rapid, dramatic anti-obsessional effects — she offers an evidence-informed, honest clinical evaluation of whether ketamine is worth trying in the context of a well-documented treatment history. Results vary by individual, and patients who approach this process with realistic expectations and genuine engagement tend to have the most productive outcomes.
A second barrier for Montana patients specifically is geographic access to ERP therapy, which is the cornerstone psychotherapy for OCD and requires a trained therapist to administer properly. Many rural Montana patients with OCD have never received adequate ERP because there are simply no trained ERP therapists within reasonable driving distance. Cassidy addresses this pragmatically: she helps patients identify telehealth-delivered ERP options, which have been validated in research as effective and which dramatically expand access for patients in geographically isolated areas. She does not treat OCD with ketamine as a replacement for ERP — she is honest about the centrality of psychotherapy to OCD management while working within the constraints of what Montana patients can realistically access. Discuss your specific situation with Cassidy, including any prior therapy history and current access to ERP, and she will give you an honest clinical perspective on what is most appropriate.
Frequently Asked Questions
Is ketamine FDA-approved for OCD?
No. Ketamine for OCD is an off-label application. It is not FDA-approved for this indication. The research base is early but mechanistically coherent and includes a published randomized clinical trial demonstrating rapid symptom reduction. Cassidy applies the same rigor of informed consent for off-label ketamine use in OCD as for any off-label application.
Do I need to have done ERP therapy before considering ketamine for OCD?
Cassidy evaluates whether prior ERP trials have been adequate before recommending ketamine. ERP, properly administered, is the most effective treatment for OCD. If you have not yet had an adequate ERP trial, Cassidy may recommend that before ketamine. If you have had adequate ERP without sufficient response, ketamine becomes more clinically appropriate to discuss.
Can ketamine make OCD worse?
There is no established evidence that ketamine worsens OCD symptoms, and the published trial literature shows symptom reduction rather than worsening. However, individual responses vary, and patients should report any changes in obsessional or compulsive symptoms between sessions to Cassidy so she can monitor the pattern across the treatment course.
What if my OCD symptoms are primarily religious or sexual in nature?
OCD presents across many different symptom domains, all of which share the same underlying neural circuitry. Cassidy evaluates OCD symptoms across all presentation types without judgment. She understands the diversity of OCD symptom content and its separateness from the patient’s values and character.
Is ketamine for OCD covered by insurance?
Mend the Mind is an out-of-network provider, and insurance coverage for IV ketamine for OCD is not established. Cassidy provides superbills for potential insurance reimbursement, and patients with co-occurring diagnoses that have more established coverage (such as TRD or PTSD) should discuss the full diagnostic picture with our office.
Key Takeaways
- OCD involves hyperactivity in glutamatergic CSTC circuits; ketamine’s NMDA blockade offers a mechanistically rational approach for treatment-resistant cases.
- Published research, including a double-blind trial in Biological Psychiatry, has demonstrated rapid OCD symptom reduction following ketamine infusion.
- At Mend the Mind, ketamine for OCD is evaluated rigorously, including prior medication and ERP therapy history.
- Cassidy incorporates OCD ketamine treatment into the broader therapeutic context, including coordination with ERP therapy when accessible.
- Results vary by individual; ketamine for OCD is off-label, and honest evaluation of your treatment history is essential before proceeding.
Conclusion
For patients with OCD that has not responded to adequate medication and therapy trials, ketamine offers a mechanistically coherent and research-supported pathway worth exploring with the right clinical guidance. At Mend the Mind in Livingston, Cassidy Boyer brings the clinical honesty, the evaluation rigor, and the integrative thinking that complex OCD presentations demand. If you are in Montana and your OCD has not responded to conventional treatment, we encourage you to schedule a consultation and have an honest conversation about what else may be possible.
References
Biological Psychiatry. Rapid anti-obsessional effects of intravenous ketamine. https://www.biologicalpsychiatryjournal.com/
National Institute of Mental Health. Obsessive-Compulsive Disorder. https://www.nimh.nih.gov/health/topics/obsessive-compulsive-disorder-ocd
International OCD Foundation. ERP Therapy. https://iocdf.org/about-ocd/treatment/
Anxiety and Depression Association of America. OCD Treatment. https://adaa.org/understanding-anxiety/obsessive-compulsive-disorder-ocd
About Cassidy Boyer, CRNA
Cassidy Boyer, CRNA, is the lead clinician at Mend The Mind in Livingston, MT, offering IV ketamine therapy and ketamine troches for adults with treatment-resistant depression, anxiety, PTSD, OCD, bipolar disorder, suicidal ideation, and chronic pain conditions including fibromyalgia, neuropathic pain, and restless legs syndrome. Boyer’s evaluation process is built on honest, detailed clinical assessment — reviewing each patient’s full prior treatment history, including medications tried, doses, duration, and response, before making any recommendation. As an out-of-network provider using the Osmind care management platform, Mend The Mind provides patients with superbills for potential insurance reimbursement after each session, combining rigorous clinical standards with direct, transparent communication about what ketamine therapy is and who it is actually appropriate for.
Medical Disclaimer
This content is provided by Mend the Mind for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Ketamine for OCD is an off-label use of an approved medication. Only a qualified medical provider can determine whether ketamine therapy is appropriate for your specific situation. Results vary by individual, and no outcomes are guaranteed. Please discuss all treatment options with your provider before making any decisions about your care.